MedTrace Logo

Mechanism(s) Underlying Cardiovascular Effects of ARB/NEP Inhibition - Aim 2

NCT03005184 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2018-01-11

No results posted yet for this study

Summary

This study tests the hypothesis that endogenous bradykinin contributes to effects of a combined angiotensin receptor blocker/neprilysin inhibitor (LCZ696 or Entresto)

Conditions

  • Heart Failure NYHA Class I
  • Heart Failure NYHA Class II
  • Heart Failure NYHA Class III

Interventions

DRUG

Valsartan 80 mg bid

oral medication during run-in and washout period

DRUG

Enalapril 10 mg bid

oral medication

DRUG

Sacubitril-Valsartan 200 mg bid

oral medication

DRUG

Icatibant

intravenous medication

DRUG

Placebo

intravenous medication

Sponsors & Collaborators

  • Vanderbilt University Medical Center

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-09-30
Primary Completion
2020-01-31
Completion
2020-01-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03005184 on ClinicalTrials.gov